New lupus pill enters human testing

NCT ID NCT06182969

Recruiting now Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called APG-2575 in 40 people with mild-to-moderate lupus. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to check safety and how the body processes the drug, not yet to see if it improves lupus symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APG-2575
What this could lead to: If this drug is safe and shows promise, it could point toward a new daily pill to help control lupus symptoms.
What could go wrong: This is an early, small study focused on safety, not on whether the drug actually helps lupus. Many drugs that look safe in early trials fail to work in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLE

Contacts and locations

Locations

Renji Hospital Shanghai Jiaotong University School of Medical
RECRUITING

Shanghai, Shanghai Municipality, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.